OPKO Health (OPK) CEO Phillip Md Et Al Frost Purchases 10,000 Shares

OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 10,000 shares of the business’s stock in a transaction on Thursday, April 19th. The stock was acquired at an average cost of $3.17 per share, for a total transaction of $31,700.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $9,728,574.67. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, April 16th, Phillip Md Et Al Frost acquired 50,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.02 per share, for a total transaction of $151,000.00.
  • On Friday, April 13th, Phillip Md Et Al Frost acquired 30,000 shares of OPKO Health stock. The stock was acquired at an average cost of $2.99 per share, for a total transaction of $89,700.00.
  • On Wednesday, April 11th, Phillip Md Et Al Frost acquired 43,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.06 per share, for a total transaction of $131,580.00.
  • On Monday, April 9th, Phillip Md Et Al Frost acquired 80,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.04 per share, for a total transaction of $243,200.00.
  • On Thursday, April 5th, Phillip Md Et Al Frost acquired 10,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.25 per share, for a total transaction of $32,500.00.
  • On Tuesday, April 3rd, Phillip Md Et Al Frost acquired 153,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.00 per share, for a total transaction of $459,000.00.
  • On Wednesday, March 28th, Phillip Md Et Al Frost acquired 80,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.07 per share, for a total transaction of $245,600.00.
  • On Monday, March 26th, Phillip Md Et Al Frost acquired 26,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.19 per share, for a total transaction of $82,940.00.
  • On Friday, March 23rd, Phillip Md Et Al Frost acquired 25,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.27 per share, for a total transaction of $81,750.00.
  • On Wednesday, March 21st, Phillip Md Et Al Frost acquired 30,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.38 per share, for a total transaction of $101,400.00.

Shares of OPK opened at $3.17 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.14 and a quick ratio of 0.98. OPKO Health has a 52-week low of $2.66 and a 52-week high of $7.90.



OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The company had revenue of $193.70 million for the quarter, compared to analysts’ expectations of $307.44 million. OPKO Health had a negative return on equity of 7.87% and a negative net margin of 28.93%. equities research analysts forecast that OPKO Health will post -0.48 earnings per share for the current fiscal year.

A number of research analysts have recently commented on OPK shares. Zacks Investment Research cut OPKO Health from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. BidaskClub raised OPKO Health from a “strong sell” rating to a “sell” rating in a research report on Friday, January 26th. JPMorgan Chase cut OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 price target on the stock. in a research report on Friday, March 2nd. ValuEngine cut OPKO Health from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Finally, Cantor Fitzgerald set a $20.00 price target on OPKO Health and gave the company a “buy” rating in a research report on Thursday, March 1st. Four investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $11.29.

Institutional investors and hedge funds have recently modified their holdings of the stock. RK Asset Management LLC lifted its holdings in OPKO Health by 8.4% during the 4th quarter. RK Asset Management LLC now owns 932,752 shares of the biotechnology company’s stock worth $4,570,000 after purchasing an additional 72,209 shares in the last quarter. X Square Capital LLC purchased a new stake in OPKO Health during the 4th quarter worth about $2,363,000. Delek Group Ltd. purchased a new stake in OPKO Health during the 4th quarter worth about $382,000. Boulegeris Investments Inc. lifted its holdings in OPKO Health by 19.3% during the 4th quarter. Boulegeris Investments Inc. now owns 228,780 shares of the biotechnology company’s stock worth $1,121,000 after purchasing an additional 36,950 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in OPKO Health by 43.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,566,433 shares of the biotechnology company’s stock worth $10,746,000 after purchasing an additional 471,256 shares in the last quarter. 23.38% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “OPKO Health (OPK) CEO Phillip Md Et Al Frost Purchases 10,000 Shares” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2018/04/20/opko-health-opk-ceo-phillip-md-et-al-frost-purchases-10000-shares.html.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply